콘텐츠로 건너뛰기
Merck
모든 사진(1)

문서

MAB1794

Sigma-Aldrich

Anti-Human B cells (CD19) Antibody, clone FMC63

clone FMC63, Chemicon®, from mouse

동의어(들):

B-lymphocyte Surface Antigen B4

로그인조직 및 계약 가격 보기


About This Item

UNSPSC 코드:
12352203
eCl@ss:
32160702
NACRES:
NA.43

생물학적 소스

mouse

Quality Level

항체 형태

purified antibody

항체 생산 유형

primary antibodies

클론

FMC63, monoclonal

종 반응성

human

제조업체/상표

Chemicon®

기술

flow cytometry: suitable
immunofluorescence: suitable

동형

IgG2a

NCBI 수납 번호

UniProt 수납 번호

배송 상태

wet ice

타겟 번역 후 변형

unmodified

유전자 정보

human ... CD19(930)

일반 설명

BIOCHEMISTRY:

p I = 7.0

특이성

This specificity of this antibody is equivalent to that of CD19 monoclonal antibodies (Zola et al., 1988, 1989), based on comparative studies, antigen recognition and positive reaction with a CD19 transfected cell line. It detects a 96 kD single chain glycoprotein on the surface of human B lineage cells, including pre-B cells. B cells can be detected in peripheral blood and tissues. The antibody reacts with most B cell malignancies including chronic lymphocytic leukemia and most lymphomas, but not multiple myeloma.

Cell reactivity:

Normal:Stains all B lymphocytes in peripheral blood and spleen. Negative on granulocytes, monocytes, platelets, erythrocytes and T lymphocytes.

Clinical:

B cell chronic lymphocytic leukemia (B-CLL) +

Pro lymphocytic leukemia (PLL) +

Hairy cell leukemia (HCL) +

Common acute lymphoblastic leukemia (CALL) +

Pre-B acute lymphoblastic leukemia (pre-B-ALL) +

NULL-acute lymphoblastic leukemia (NULL-ALL) +

T common lymphocytic leukemia (T-CLL) -

면역원

Raji cells

애플리케이션

Research Category
Inflammation & Immunology
Research Sub Category
Immunoglobulins & Immunology
This Anti-Human B cells CD19 Antibody, clone FMC63 is validated for use in FC, IF for the detection of CD19.
This antibody is useful for enumerating normal B lymphocytes and typing B cell malignancies by flow cytometry and immunofluorescence.

SUGGESTED USAGE DILUTION

Flow cytometry and Indirect Immunofluorescence 1:25

Dilute with isotonic buffer. Use 50 μl of diluted antibody per 1 x 10E6 peripheral blood mononuclear cells (PBMC) in 100 μl buffer.

결합

Replaces: CBL141

물리적 형태

Format: Purified
Purified from mouse ascitic fluid. The antibody is supplied in 25 mM Tris-HCl buffer, 0.4 M NaCl, pH 8.0, containing 0.2% bovine serum albumin and 0.1% sodium azide. The characteristics of each lot are tested by electrophoresis and flow cytometry.

저장 및 안정성

Store at 2 to 8°C, for up to 6 months. For prolonged periods, store below -20°C in undiluted aliquots. AVOID REPEATED FREEZE/THAW CYCLES.

WARNING: The monoclonal reagent solution contains 0.1% sodium azide as a preservative. Due to potential hazards arising from the build up of this material in pipes, spent reagent should be disposed of with liberal volumes of water.

기타 정보

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

법적 정보

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

면책조항

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

적합한 제품을 찾을 수 없으신가요?  

당사의 제품 선택기 도구.을(를) 시도해 보세요.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Xing Du et al.
Cancer research, 68(15), 6300-6305 (2008-08-05)
B-cell malignancies routinely express surface antigens CD19 and CD22. Immunotoxins against both antigens have been evaluated, and the immunotoxins targeting CD22 are more active. To understand this disparity in cytotoxicity and guide the screening of therapeutic targets, we compared two
Christine Ambrose et al.
PloS one, 16(3), e0247701-e0247701 (2021-03-19)
Successful CAR T cell therapy for the treatment of solid tumors requires exemplary CAR T cell expansion, persistence and fitness, and the ability to target tumor antigens safely. Here we address this constellation of critical attributes for successful cellular therapy
Fabiana Zappala et al.
Science advances, 8(18), eabn4613-eabn4613 (2022-05-07)
Extensive antibody engineering and cloning is typically required to generate new bispecific antibodies. Made-to-order genes, advanced expression systems, and high-efficiency cloning can simplify and accelerate this process, but it still can take months before a functional product is realized. We
Stephanie N Shishido et al.
Journal for immunotherapy of cancer, 12(2) (2024-02-14)
Chimeric antigen receptor (CAR)-T cells are approved for use in the treatment of hematological malignancies. Axicabtagene ciloleucel (YESCARTA) and brexucabtagene autoleucel (TECARTUS) genetically modified autologous T cells expressing an anti-CD19 scFv based on the FMC63 clone have shown impressive response
Ye Lin et al.
Frontiers in neurology, 13, 808322-808322 (2022-03-18)
Myasthenia gravis (MG) is an autoimmune disease mediated by B cells secreting autoantibodies. Regulatory B (Breg) cells confirmed to have an immunosuppressive function play an important role in many autoimmune diseases. However, what about the changes in Breg cells in

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.